In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Theregen Corp.

www.theregencompany.com

Latest From Theregen Corp.

The New World Of Device Venture Investing: Same As The Old World?

At Elsevier Business Intelligence's February IN3 West conference, a panel of leading device venture investors, who remain committed to and are actively doing deals in medtech, discussed how the recent recession has affected device investing and how much, if at all, that world has changed as a result.
Medical Device

Succeeding in Heart Failure, Incrementally

Because of the heterogeneity of heart failure patients and causes, new drugs to treat heart failure haven't been a huge area of research or business development. Few heart failure drugs are likely to be blockbusters, and there are very few deals around truly novel targets. Biotech start-ups build on known approaches and innovate incrementally, in this market.
BioPharmaceutical Strategy

Theregen Corp.

Theregen Corp.'s Anginera is a cell-based epicardial patch designed to promote blood vessel growth in ischemic cardiac tissue. Numerous animal studies have demonstrated that Anginera-which is based on the Dermagraft wound repair patch--promotes angiogenesis and arteriogenesis in ischemic tissue, and may also preserve or repair cardiac function in the failing heart.
BioPharmaceutical Medical Device

In Cardiac Regeneration, it's Repair, not Replace

Recent clinical trial failures in cardiac stem cell therapies have been widely reported as raising more questions than answers in a field which already had many unknowns. But those questions themselves give rise to new strategies spurring the formation of start-ups like those profiled in this issue. While the new companies are ultimately addressing heart failure, they hope to intervene much earlier in the cascade of damage and remodeling, where turning up the body's natural healing responses a notch could help it repair the damage caused by myocardial infarction or ischemia. Many cardiac cell and gene therapy companies are returning to ischemic disease, a field in which, in recent years, the success of device-based revascularization techniques appeared to present a competitive hurdle to cell and gene therapies. Microvessel disease is emerging as a large market in which cell and gene therapies might have advantages over devices.
Regenerative Medicine
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Medical Devices
    • Biomaterials
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Iken Tissue Therapeutics Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Theregen Corp.
  • Senior Management
  • Thomas A Schreck, CEO
    Gary D Gentzkow, MD, CMO
  • Contact Info
  • Theregen Corp.
    Phone: (415) 439-8320
    225 Bush St.
    16th Fl.
    San Francisco, CA 94105
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register